Investor Presentaiton

% Patients with EASI-75 ONENESS Efficacy vs Dupixent Sanofi's Dupixent (dupilumab) current best-selling biologic drug for moderate-to-severe AD 9x 69.0% FB825 2x 67% 70% 62.6% 60% 50% 40% 30% 20% 10% 0% q12w + TCS q2w + TCS qw + TCS dupilumab Ph3 trial Comparison between trials: FB825 first-patient trial (NCT0358716) vs. 2 Phase III trial of Dupixent PBO + TCS q2w + TCS qw + TCS dupilumab Ph3 trial PBO + TCS | 18

View entire presentation